연구 및 보고서

Anguk Pharmaceutical and radiopharmaceutical specialist Selbion have signed an MOU to collaborate on innovative radiopharmaceutical therapies and discover new oncology drug pipelines.

HK Innoen’s VP Song Geun‑seok was honored with the 3rd‑class Science and Technology Medal for 33 years of drug‑development R&D and innovation at the 2026 Technology Developer’s Day ceremony.

The National New Drug Development Foundation wrapped up its 2026 KDDF Science Conference on Aug 27‑28 at Pyeongchang Alpensia Resort, focusing on science‑driven translation from discovery to patient benefit.

VAXDIGM has been selected for a Ministry of Health‑and‑Welfare and KHIDI‑backed R&D project to create antiviral therapies targeting the replication platform of RNA viruses such as SARS‑CoV‑2.

Dong-A ST disclosed nonclinical results for its Alzheimer’s drug candidates targeting ferroptosis (DA-7505) and tau aggregation (DA-7503) at the AAIC in London.

Samsung Bioepis and Proteina signed a license option agreement to advance AI‑driven antibody drug discovery from candidate identification to commercialization, building on a government AI project.

Jongkundang has established NURATEON, a dedicated R&D subsidiary offering full‑cycle drug development services, from new formulations to DDS research.

LigaChem Bio presented its 2035 R&D roadmap, aiming to enhance its ADC platform, explore non‑oncology indications and boost next‑generation drug success through patient‑centric research.

Mokam Life Science Institute and ST Pharm have signed a joint R&D agreement to develop AI‑based RNA design and optimization technology, aiming to boost next‑generation RNA therapeutic development.